Episode 19: Dealable — Oct 31: Trillion-Dollar AI, Billion-Dollar Biotech

Dec 9

Written By Brian O'Neill

Pocket Casts (Copy) (Copy) (Copy) (Copy) (Copy) (Copy) (Copy) (Copy) (Copy) (Copy) (Copy) (Copy) (Copy) (Copy) (Copy) (Copy) (Copy) (Copy)

Castro (Copy) (Copy) (Copy) (Copy) (Copy) (Copy) (Copy) (Copy) (Copy) (Copy) (Copy) (Copy) (Copy) (Copy) (Copy) (Copy) (Copy) (Copy)

Goodpods (Copy) (Copy) (Copy) (Copy) (Copy) (Copy) (Copy) (Copy) (Copy) (Copy) (Copy) (Copy) (Copy) (Copy) (Copy) (Copy) (Copy) (Copy)

Metacast (Copy) (Copy) (Copy) (Copy) (Copy) (Copy) (Copy) (Copy) (Copy) (Copy) (Copy) (Copy) (Copy) (Copy) (Copy) (Copy) (Copy) (Copy)

OpenAI is racing toward a trillion-dollar valuation while burning tens of billions on chips, data centers, and Azure commitments. We break down the new capital structure, Microsoft’s leverage, why Zuck is FOMO-building compute, and whether OpenAI should even want to be a public company. Also: the underrated bottlenecks—power, foundries, CUDA, China—and why this boom feels like 1999 with actual revenue.

Then we jump to biotech to cover the Pfizer and Novo bidding war for Metsera (Pfizer ultimately won with its $8 billion deal). The bidding for Metesera drew at least six bidders and may set-off a chain reaction in the GLP-1 space. We speculate on what this deal might mean for Viking (VKTX) and others in the GLP-1 / obesity space.

Get Email Updates

Brian O'Neill

Episode 19: Dealable — Oct 31: Trillion-Dollar AI, Billion-Dollar Biotech

Episode 20: IonQ Update, November 2025

Episode 18: AI Eats Everything